Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Migraine Breakthrough at Xi'an Jiaotong-Liverpool University could lead to Improved Drugs

Xi'an Jiaotong-Liverpool University
Posted on: 16 Nov 16

PR Newswire

LONDON, Nov. 16, 2016

LONDON, Nov. 16, 2016 /PRNewswire/ -- A PhD student at Xi'an Jiaotong-Liverpool University in Suzhou, China is carrying out work that could have a significant impact on drugs developed to prevent and treat migraines.

Fan Bu's doctoral project has revealed a previously unknown mechanism, involving a protein within brain cells, which plays a key role in a migraine starting and developing.

When the protein that Fan has identified, named sarcoma family kinases, is activated in cells in the brain it can lead to the neurological responses that may trigger migraines.

"We knew that this protein existed and it was involved in other diseases," he said, "but we had not known its significant involvement in migraines until I studied the underlying mechanism of a key subunit of a cell membrane protein associated with migraine, that had been identified in the early stages of my PhD project."

It is thought that if the activity of this enzyme can be prohibited, migraines may be prevented from occurring at all. The discovery has potential importance in identifying targeted drugs for preventing migraines.

More than one billion people -- around 16 percent of world's population -- regularly suffer the debilitating symptoms of migraines.

In the past, scientists believed that migraines were linked to the changes of blood flow in the brain. It is now believed, however, that migraines are also caused by inherited abnormalities in genes that control the activities of certain brain cells. 

"There are currently no cures for migraines, the most effective thing is for people to prevent them from happening," said Fan. "My work will contribute to the ongoing drug development that might ultimately discover cures, which is very exciting."

Fan's work has been carried out under the supervision of Dr Minyan Wang, associate professor and director of the Centre for Neuroscience at XJTLU, currently the only research centre in China dedicated to migraine research and drug development.

The Centre for Neuroscience, founded in 2013, has state-of-the-art facilities and talented researchers working on a number of projects across a variety of migraine research systems and migraine models.

Founded in 2006, XJTLU is the largest international joint venture university in China, a partnership between Xi'an Jiaotong University and the University of Liverpool. Our vision is to become a research-led international university in China and a Chinese university recognised internationally for its unique features.

Photo - http://photos.prnewswire.com/prnh/20161116/440035

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/migraine-breakthrough-at-xian-jiaotong-liverpool-university-could-lead-to-improved-drugs-300363996.html

SOURCE Xi'an Jiaotong-Liverpool University

PR Newswire
www.prnewswire.com

Last updated on: 16/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.